

7. Literaturverzeichnis

- Andren, O., K. Fall, et al. (2006). "How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden." J Urol **175**(4): 1337-40.
- Anglesio, S., E. Calamia, et al. (2005). "Prostate brachytherapy with iodine-125 seeds: radiation protection issues." Tumori **91**(4): 335-8.
- Aslan, G., B. Irer, et al. (2005). "The value of PSA, free-to-total PSA ratio and PSA density in the prediction of pathologic stage for clinically localized prostate cancer." Int Urol Nephrol **37**(3): 511-4.
- Ataus, S., A. Citci, et al. (1999). "The value of serum prostate specific antigen and other parameters in detecting bone metastases in prostate cancer." Int Urol Nephrol **31**(4): 481-9.
- Bagshaw, M. A. (1969). "Definitive radiotherapy in carcinoma of the prostate." Jama **210**(2): 326-7.
- Bahnon, R. R., G. E. Hanks, et al. (2000). "NCCN Practice Guidelines for Prostate Cancer." Oncology (Williston Park) **14**(11A): 111-9.
- Baltogiannis, D., X. Giannakopoulos, et al. (2004). "Monotherapy in advanced prostate cancer: an overview." Exp Oncol **26**(3): 185-91.
- Bangma, C. H. (2000). "[Mass screening for detection of prostatic carcinoma]." Urologe A **39**(4): 334-40.
- Bastacky, S. I., K. J. Wojno, et al. (1995). "Pathological features of hereditary prostate cancer." J Urol **153**(3 Pt 2): 987-92.
- Blute, M. L., E. J. Bergstralh, et al. (2001). "Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy." J Urol **165**(1): 119-25.
- Boehmer, A., A. G. Anastasiadis, et al. (2005). "Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: a single-center experience." Anticancer Res **25**(6C): 4481-6.
- Bonhomme, C., C. Choquenot, et al. (2000). "[Radiotherapy of localized prostatic cancer: follow-up of 48 patients. G.C.C.P. (Cooperative Group for the Study of Prostatic Cancer)]." Ann Urol (Paris) **34**(1): 32-8.

- Bostwick, D. G. (1994). "Gleason grading of prostatic needle biopsies. Correlation with grade in 316 matched prostatectomies." Am J Surg Pathol **18**(8): 796-803.
- Bott, S. R., A. A. Freeman, et al. (2005). "Radical prostatectomy: pathology findings in 1001 cases compared with other major series and over time." BJU Int **95**(1): 34-9.
- Brassell, S. A., T. C. Kao, et al. (2005). "Prostate-specific antigen versus prostate-specific antigen density as predictor of tumor volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer." Urology **66**(6): 1229-33.
- Brawer, M. K. and P. H. Lange (1989). "Prostate-specific antigen in management of prostatic carcinoma." Urology **33**(5 Suppl): 11-6.
- Brawley, O. W. and S. Barnes (2001). "The epidemiology of prostate cancer in the United States." Semin Oncol Nurs **17**(2): 72-7.
- Brawley, O. W., S. Barnes, et al. (2001). "The future of prostate cancer prevention." Ann N Y Acad Sci **952**: 145-52.
- Breslow, N., C. W. Chan, et al. (1977). "Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France." Int J Cancer **20**(5): 680-8.
- Brossner, C., S. Madersbacher, et al. (2005). "Follow-up of men obtaining a six-core versus a ten-core benign prostate biopsy 7 years previously." World J Urol **23**(6): 419-21.
- Bunting, P. S. (2002). "Screening for prostate cancer with prostate-specific antigen: beware the biases." Clin Chim Acta **315**(1-2): 71-97.
- Candas, B., L. Cusan, et al. (2000). "Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer." Prostate **45**(1): 19-35.
- Carter, B. S., G. S. Bova, et al. (1993). "Hereditary prostate cancer: epidemiologic and clinical features." J Urol **150**(3): 797-802.
- Catalona, W. J., A. W. Partin, et al. (1999). "Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model." Urology **54**(2): 220-4.
- Catalona, W. J., J. P. Richie, et al. (1994). "Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men." J Urol **151**(5): 1283-90.

- Catalona, W. J., P. C. Southwick, et al. (2000). "Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging." Urology **56**(2): 255-60.
- Cheng, L., H. Zincke, et al. (2001). "Risk of prostate carcinoma death in patients with lymph node metastasis." Cancer **91**(1): 66-73.
- Colella, J., S. Scrofine, et al. (2006). "Prostate HDR radiation therapy: a comparative study evaluating the effectiveness of pain management with peripheral PCA vs. PCEA." Urol Nurs **26**(1): 57-61.
- Cornud, F., M. F. Bellin, et al. (2006). "[MRI and staging evaluation of prostate cancer]." J Radiol **87**(2 Pt 2): 228-43.
- Corvin, S., D. Schilling, et al. (2006). "Laparoscopic sentinel lymph node dissection--a novel technique for the staging of prostate cancer." Eur Urol **49**(2): 280-5.
- Cosset, J. M. and C. Haie-Meder (2005). "[Brachytherapy for prostate cancer: high dose rate or low-dose rate?]." Cancer Radiother **9**(8): 610-9.
- Crook, J. (2005). "Androgen suppression therapy, in combination with radiotherapy prolongs overall survival in men with clinically localised prostate cancer." Cancer Treat Rev **31**(1): 53-7.
- Dahm, P., B. K. Yang, et al. (2005). "Radical perineal prostatectomy for the treatment of localized prostate cancer in morbidly obese patients." J Urol **174**(1): 131-4.
- Deguchi, T., M. Yang, et al. (1997). "Prostate cancer micrometastases to lymph nodes." Urology **50**(5): 826-7.
- Dillioglulugil, O., B. D. Leibman, et al. (1997). "Risk factors for complications and morbidity after radical retropubic prostatectomy." J Urol **157**(5): 1760-7.
- Djavan, B., P. Mazal, et al. (2001). "Pathological features of prostate cancer detected on initial and repeat prostate biopsy: results of the prospective European Prostate Cancer Detection study." Prostate **47**(2): 111-7.
- Drudge-Coates, L. (2005). "Prostate cancer and the principles of hormone therapy." Br J Nurs **14**(7): 368-75.
- Duffy, M. J. (1996). "PSA as a marker for prostate cancer: a critical review." Ann Clin Biochem **33** (Pt 6): 511-9.
- Dyrstad, S. W., P. Shah, et al. (2006). "Chemotherapy for prostate cancer." Curr Pharm Des **12**(7): 819-37.
- Ekman, P. (1997). "Predicting pelvic lymph node involvement in patients with localized prostate cancer." Eur Urol **32 Suppl 3**: 60-4.

- El-Galley, R. E., T. E. Keane, et al. (1998). "Evaluation of staging lymphadenectomy in prostate cancer." Urology **52**(4): 663-7.
- Ellis, W. J., R. Etzioni, et al. (2001). "Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer." J Urol **166**(1): 93-8; discussion 98-9.
- Epstein, J. I., W. C. Allsbrook, Jr., et al. (2006). "Update on the Gleason grading system for prostate cancer: results of an international consensus conference of urologic pathologists." Adv Anat Pathol **13**(1): 57-9.
- Eskicorapci, S. Y., D. E. Baydar, et al. (2004). "An extended 10-core transrectal ultrasonography guided prostate biopsy protocol improves the detection of prostate cancer." Eur Urol **45**(4): 444-8; discussion 448-9.
- Fichtner, J., D. Mengesha, et al. (2004). "Feasibility of radical perineal prostatectomy under spinal anaesthesia." BJU Int **94**(6): 802-4.
- Fischer, C. G., W. Waechter, et al. (1998). "Urologic tumors in the Federal Republic of Germany: data on 56,013 cases from hospital cancer registries." Cancer **82**(4): 775-83.
- Fournier, G., A. Valeri, et al. (2004). "[Prostate cancer. Epidemiology. Risk factors. Pathology]." Ann Urol (Paris) **38**(5): 187-206.
- Fournier, G., A. Valeri, et al. (2004). "[Prostate cancer: Diagnosis and staging]." Ann Urol (Paris) **38**(5): 207-24.
- Gademann, G. (1994). "[Radiotherapy of prostatic cancer]." Radiologe **34**(3): 134-43.
- Gann, P. H. and M. Han (2005). "The natural history of clinically localized prostate cancer." Jama **293**(17): 2149-51.
- Gleason, D. F. (1966). "Classification of prostatic carcinomas." Cancer Chemother Rep **50**(3): 125-8.
- Goeman, L., L. Salomon, et al. (2006). "Long-term functional and oncological results after retroperitoneal laparoscopic prostatectomy according to a prospective evaluation of 550 patients." World J Urol.
- Grayhack, J. T. and D. G. Assimos (1983). "Prognostic significance of tumor grade and stage in the patient with carcinoma of the prostate." Prostate **4**(1): 13-31.
- Guillonnet, B., X. Cathelineau, et al. (1999). "Laparoscopic radical prostatectomy: technical and early oncological assessment of 40 operations." Eur Urol **36**(1): 14-20.

- Hamburg (2001). "Latent prostatic carcinoma. Proceedings of a symposium. Hamburg, Germany, November 2-4, 2000." Eur Urol **39 Suppl 4**: 1-54.
- Hammerer, P., M. Graefen, et al. (2000). "[Chemoprevention of prostatic carcinoma]." Urologe A **39**(4): 304-8.
- Han, M., A. W. Partin, et al. (2001). "Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience." Urol Clin North Am **28**(3): 555-65.
- Harris, M. J. and I. M. Thompson, Jr. (1996). "The anatomic radical perineal prostatectomy: a contemporary and anatomic approach." Urology **48**(5): 762-8.
- Heidenreich, A. (2005). "[Therapy of hormone-refractory prostate cancer]." Urologe A **44**(12): 1481-94; quiz 1495.
- Heidenreich, A. and C. H. Ohlmann (2005). "[The role of pelvic lymphadenectomy in the therapy of prostate and bladder cancer]." Aktuelle Urol **36**(3): 219-29.
- Heidenreich, A., Z. Varga, et al. (2002). "Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis." J Urol **167**(4): 1681-6.
- Heinzer, H., M. Graefen, et al. (1997). "Early complication of anatomical radical retropubic prostatectomy: lessons from a single-center experience." Urol Int **59**(1): 30-3.
- Helpap, B. (1998). Atlas der Pathologie urologischer Tumoren. Heidelberg.
- Hilz, H. (1995). "[Molecular forms of prostate-specific antigen and their clinical significance]." Urologe A **34**(4): 275-82.
- Hocht, S., T. Wiegel, et al. (2002). "Adjuvant and salvage radiotherapy after radical prostatectomy." Onkologie **25**(3): 201-6.
- Hohbach, C. and G. Dhom (1980). "Pathology of prostatic cancer." Scand J Urol Nephrol Suppl **55**: 37-47.
- Igel, T. C. and M. J. Wehle (1999). "Vesicourethral reconstruction in radical retropubic prostatectomy: an alternative technique." J Urol **161**(3): 844-6.
- Ismail, M. and L. G. Gomella (2001). "Ultrasound for prostate imaging and biopsy." Curr Opin Urol **11**(5): 471-7.
- Jakse, G., E. Manegold, et al. (2000). "[Expanded, radical perineal prostatectomy]." Urologe A **39**(5): 455-62.
- Janetschek, G. (2005). "Pelvic lymph node dissection in prostate cancer: editorial review." Curr Opin Urol **15**(2): 65-7.

- Jeschke, S., T. Nambirajan, et al. (2005). "Detection of early lymph node metastases in prostate cancer by laparoscopic radioisotope guided sentinel lymph node dissection." J Urol **173**(6): 1943-6.
- Jewett, H. J. (1972). "Rubin H. Flocks and the prostatic disease center." J Iowa Med Soc **62**(11): 572-5.
- John, E. M., A. S. Whittemore, et al. (1995). "Vasectomy and prostate cancer: results from a multiethnic case-control study." J Natl Cancer Inst **87**(9): 662-9.
- Jung, K., B. Brux, et al. (1999). "Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA." Urology **53**(6): 1160-7; discussion 1167-8.
- Kattan, M. W., T. M. Wheeler, et al. (1999). "Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer." J Clin Oncol **17**(5): 1499-507.
- Kelloff, G. J., R. Lieberman, et al. (2001). "Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer." Urology **57**(4 Suppl 1): 46-51.
- Kirby, R. (2005). "Locally advanced prostate cancer treated with radiotherapy and androgen deprivation." Nat Clin Pract Urol **2**(6): 304-8.
- Klotz, L., H. Payne, et al. (2005). "[Reevaluation of MAB therapy and progress of endocrine therapy]." Gan To Kagaku Ryoho **32**(5): 705-28.
- Klotz, L. H. and R. K. Nam (2006). "Active surveillance with selective delayed intervention for favorable risk prostate cancer: clinical experience and a 'number needed to treat' analysis." Can J Urol **13 Suppl 1**: 48-55.
- Korman, H. J., P. B. Leu, et al. (2002). "A centralized comparison of radical perineal and retropubic prostatectomy specimens: is there a difference according to the surgical approach?" J Urol **168**(3): 991-4.
- Krebsregister (2002). Krebs in Deutschland. Saarbrücken, Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland.
- Kupelian, P., J. Katcher, et al. (1996). "Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer." Urology **48**(2): 249-60.
- Kupelian, P. A. and T. R. Willoughby (2001). "Short-course, intensity-modulated radiotherapy for localized prostate cancer." Cancer J **7**(5): 421-6.

- Kuriyama, M., R. Loo, et al. (1982). "Prostatic acid phosphatase and prostate-specific antigen in prostate cancer." Int Adv Surg Oncol **5**: 29-49.
- Kuriyama, M., K. Obata, et al. (1996). "Serum prostate-specific antigen values for the prediction of clinical stage and prognosis in patients with prostate cancer: an analysis of 749 cases." Int J Urol **3**(6): 462-7.
- Lagerveld, B. W., M. P. Laguna, et al. (2003). "Long-term results after external beam radiation therapy for T1-T2 localized prostate cancer." Curr Urol Rep **4**(3): 240-7.
- Lance, R. S., P. A. Freidrichs, et al. (2001). "A comparison of radical retropubic with perineal prostatectomy for localized prostate cancer within the Uniformed Services Urology Research Group." BJU Int **87**(1): 61-5.
- Lawton, C. A., M. Won, et al. (1991). "Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706." Int J Radiat Oncol Biol Phys **21**(4): 935-9.
- Lein, M., K. Jung, et al. (1999). "Re: Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples." J Urol **162**(2): 502-3.
- Lein, M., K. Jung, et al. (2001). "Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis." Eur Urol **39**(1): 57-64.
- Li, M. C., G. Kanwal, et al. (1973). "Prostatic tumor acid phosphatase production. Influence of antineoplastic agents." Urology **1**(3): 221-5.
- Lilja, H., A. Christensson, et al. (1991). "Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin." Clin Chem **37**(9): 1618-25.
- Lilleby, W., G. Torlakovic, et al. (2001). "Prognostic significance of histologic grading in patients with prostate carcinoma who are assessed by the Gleason and World Health Organization grading systems in needle biopsies obtained prior to radiotherapy." Cancer **92**(2): 311-9.
- Littrup, P. J., R. A. Kane, et al. (1994). "Cost-effective prostate cancer detection. Reduction of low-yield biopsies. Investigators of the American Cancer Society National Prostate Cancer Detection Project." Cancer **74**(12): 3146-58.
- Litwin, M. S., G. Y. Melmed, et al. (2001). "Life after radical prostatectomy: a longitudinal study." J Urol **166**(2): 587-92.

- Loch, T., I. Leuschner, et al. (1999). "Artificial neural network analysis (ANNA) of prostatic transrectal ultrasound." Prostate **39**(3): 198-204.
- Lopez, M., L. Montes De Oca, et al. (1996). "[Correlation between specific prostatic antigen and findings with total body bone scintigraphy]." Arch Esp Urol **49**(9): 953-5.
- Lynch, H. T., A. L. Larsen, et al. (1966). "Prostate carcinoma and multiple primary malignancies. Study of a family and 109 consecutive prostate cancer patients." Cancer **19**(12): 1891-7.
- Mai, K. T., P. A. Isotalo, et al. (2000). "Incidental prostatic adenocarcinomas and putative premalignant lesions in TURP specimens collected before and after the introduction of prostate-specific antigen screening." Arch Pathol Lab Med **124**(10): 1454-6.
- Makridakis, N., R. K. Ross, et al. (1997). "A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase." Cancer Res **57**(6): 1020-2.
- Manseck, A., T. Benusch, et al. (1997). "[Value of PSA density determination in prostate carcinoma]." Urologe A **36**(4): 323-6.
- Marshall, J. R. (2001). "High-grade prostatic intraepithelial neoplasia as an exposure biomarker for prostate cancer chemoprevention research." IARC Sci Publ **154**: 191-8.
- McWhorter, W. P., A. D. Hernandez, et al. (1992). "A screening study of prostate cancer in high risk families." J Urol **148**(3): 826-8.
- Merrill, R. M. (2001). "Demographics and health-related factors of men receiving prostate-specific antigen screening in Utah." Prev Med **33**(6): 646-52.
- Messing, E. M., J. Manola, et al. (1999). "Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer." N Engl J Med **341**(24): 1781-8.
- Miller, M. (2001). "Cancer incidence trends differ between Europe, United States." J Natl Cancer Inst **93**(19): 1444-5.
- Mostofi, F. K. (1975). "Grading of prostatic carcinoma." Cancer Chemother Rep **59**(1): 111-7.
- Mostofi, F. K., C. J. Davis, Jr., et al. (1992). "Pathology of carcinoma of the prostate." Cancer **70**(1 Suppl): 235-53.

- Moul, J. W. and F. Saad (2005). "Low-risk prostate cancer patient: active treatment." Can J Urol **12 Suppl 2**: 25-7.
- Muir, C. S., J. Nectoux, et al. (1991). "The epidemiology of prostatic cancer. Geographical distribution and time-trends." Acta Oncol **30**(2): 133-40.
- Ng, T. K., D. Vasilareas, et al. (2005). "Prostate cancer detection with digital rectal examination, prostate-specific antigen, transrectal ultrasonography and biopsy in clinical urological practice." BJU Int **95**(4): 545-8.
- Ozden, E., A. T. Turgut, et al. (2005). "Follow-up of the transrectal ultrasonographic features of the prostate after biopsy: does any ultrasonographically detectable lesion form secondary to the first biopsy?" J Ultrasound Med **24**(12): 1659-63.
- Parker, C. (2004). "Active surveillance of early prostate cancer: rationale, initial results and future developments." Prostate Cancer Prostatic Dis **7**(3): 184-7.
- Parkinson, M. C., S. R. Bott, et al. (2002). "Screening for prostatic cancer and its evolution within Britain." J Pathol **197**(2): 139-42.
- Partin, A. W., M. W. Kattan, et al. (1997). "Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update." Jama **277**(18): 1445-51.
- Partin, A. W., L. A. Mangold, et al. (2001). "Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium." Urology **58**(6): 843-8.
- Pearce, A., R. Choo, et al. (2006). "Effect of combined treatment with salvage radiotherapy plus androgen suppression on quality of life in patients with recurrent prostate cancer after radical prostatectomy." Int J Radiat Oncol Biol Phys.
- Penner, D. W. (1989). "An overview of the College of American Pathologists' programs in surgical pathology and cytopathology. Data summary of diagnostic performance in cervical cytopathology." Acta Cytol **33**(4): 439-42.
- Perrin, P. (2006). "PSA velocity and prostate cancer detection: the absence of evidence is not the evidence of absence." Eur Urol **49**(3): 418-9.
- Petrylak, D. (2005). "Therapeutic options in androgen-independent prostate cancer: building on docetaxel." BJU Int **96 Suppl 2**: 41-6.
- Polascik, T. J., J. E. Oesterling, et al. (1999). "Prostate specific antigen: a decade of discovery--what we have learned and where we are going." J Urol **162**(2): 293-306.

- Potosky, A. L., E. J. Feuer, et al. (2001). "Impact of screening on incidence and mortality of prostate cancer in the United States." Epidemiol Rev **23**(1): 181-6.
- Potosky, A. L., J. Legler, et al. (2000). "Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study." J Natl Cancer Inst **92**(19): 1582-92.
- Pound, C. R., A. W. Partin, et al. (1999). "Natural history of progression after PSA elevation following radical prostatectomy." Jama **281**(17): 1591-7.
- Presti, J. C., Jr. (2000). "Prostate cancer: assessment of risk using digital rectal examination, tumor grade, prostate-specific antigen, and systematic biopsy." Radiol Clin North Am **38**(1): 49-58.
- Puppo, P., M. Perachino, et al. (1994). "Laparoscopic pelvic lymphnodes dissection for prostate and bladder cancer: indication, techniques and results." Arch Ital Urol Androl **66**(3): 117-23.
- Raja, J., N. Ramachandran, et al. (2006). "Current status of transrectal ultrasound-guided prostate biopsy in the diagnosis of prostate cancer." Clin Radiol **61**(2): 142-53.
- Ray, G. R., J. R. Cassady, et al. (2002). "Definitive radiation therapy of carcinoma of the prostate. A report on 15 years of experience. 1973." J Urol **167**(2 Pt 2): 990-8.
- Reynard, J. M., T. J. Peters, et al. (1995). "Prostate-specific antigen and prognosis in patients with metastatic prostate cancer--a multivariable analysis of prostate cancer mortality." Br J Urol **75**(4): 507-15.
- Roach, M., 3rd, C. Marquez, et al. (1994). "Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer." Int J Radiat Oncol Biol Phys **28**(1): 33-7.
- Rodriguez Alonso, A., A. Gonzalez Blanco, et al. (2005). "[Prostate cancer diagnosis using 24 cores extended biopsy]." Actas Urol Esp **29**(10): 934-42.
- Rodriguez-Patron Rodriguez, R., T. Mayayo Dehesa, et al. (2005). "[The role of prostate volume in ultrasound guided transrectal prostate biopsy: is it as important as a marker as PSA?]." Arch Esp Urol **58**(9): 903-13.
- Roy, C., V. Servois, et al. (2006). "[Treatments of prostate carcinoma and imaging follow up]." J Radiol **87**(2 Pt 2): 244-56.
- Rozet, F., M. Galiano, et al. (2005). "Extraperitoneal laparoscopic radical prostatectomy: a prospective evaluation of 600 cases." J Urol **174**(3): 908-11.

- Ruebben, H., A. Bex, et al. (2001). "Systemic treatment of hormone refractory prostate cancer." World J Urol **19**(2): 99-110.
- Ruijter, E., G. van Leenders, et al. (2000). "Errors in histological grading by prostatic needle biopsy specimens: frequency and predisposing factors." J Pathol **192**(2): 229-33.
- Ruoppolo, M. (2005). "Early diagnosis of prostatic cancer: disease-related survival improvement or extension of observation time?" Arch Ital Urol Androl **77**(3): 169-72.
- Ryan, C. J. and E. J. Small (2006). "Prostate cancer update: 2005." Curr Opin Oncol **18**(3): 284-8.
- Sakai, I., K. Harada, et al. (2006). "Usefulness of the nadir value of serum prostate-specific antigen measured by an ultrasensitive assay as a predictor of biochemical recurrence after radical prostatectomy for clinically localized prostate cancer." Urol Int **76**(3): 227-31.
- Sakr, W. A. and A. W. Partin (2001). "Histological markers of risk and the role of high-grade prostatic intraepithelial neoplasia." Urology **57**(4 Suppl 1): 115-20.
- Salem, C. E., C. K. Hoh, et al. (2006). "A preclinical study of prostate sentinel lymph node mapping with [99mTc]diethylenetetramine pentaacetic acid-mannosyl-dextran." J Urol **175**(2): 744-8.
- Salesi, N., P. Carlini, et al. (2005). "Prostate cancer: the role of hormonal therapy." J Exp Clin Cancer Res **24**(2): 175-80.
- Sandberg, A. A. (1992). "Chromosomal abnormalities and related events in prostate cancer." Hum Pathol **23**(4): 368-80.
- Schaefer, U., F. Witt, et al. (2000). "Prostate-specific antigen (PSA) in the monitoring of prostate cancer after radical prostatectomy and external beam radiation." Anticancer Res **20**(6D): 4989-92.
- Schild, S. E. and T. M. Pisansky (2001). "The role of radiotherapy after radical prostatectomy." Urol Clin North Am **28**(3): 629-37, x.
- Schroder, F. H., F. E. Alexander, et al. (2000). "Screening and early detection of prostate cancer." Prostate **44**(3): 255-63.
- Schumacher, M., F. C. Burkhard, et al. (2005). "[The role of pelvic lymphadenectomy in clinically localised prostate cancer]." Urologe A **44**(6): 645-51.
- Schumacher, M., G. N. Thalmann, et al. (2006). "[Radical prostatectomy in the treatment of organ confined prostate cancer]." Ther Umsch **63**(2): 143-50.

- Seegenschmiedt, M. H. and R. Oppenkowski (2001). "[Radiotherapy and bisphosphonate therapy in bone metastases of prostate carcinoma]." Schweiz Rundsch Med Prax **90**(38): 1645-52.
- Shibata, A. and A. S. Whittemore (2001). "Re: Prostate cancer incidence and mortality in the United States and the United Kingdom." J Natl Cancer Inst **93**(14): 1109-10.
- Siegsmund, M., A. Musial, et al. (2001). "[Ldr brachytherapy, a minimally invasive alternative in the treatment of organ-confined prostate cancer]." Onkologie **24 Suppl 5**: 46-50.
- Smith, D. S. and W. J. Catalona (1995). "Interexaminer variability of digital rectal examination in detecting prostate cancer." Urology **45**(1): 70-4.
- Soloway, M. and M. Roach, 3rd (2005). "Prostate cancer progression after therapy of primary curative intent: a review of data from prostate-specific antigen era." Cancer **104**(11): 2310-22.
- Song, C., T. Kang, et al. (2005). "Nomograms for the prediction of pathologic stage of clinically localized prostate cancer in Korean men." J Korean Med Sci **20**(2): 262-6.
- Sooriakumaran, P., S. J. Khaksar, et al. (2006). "Management of prostate cancer. Part 2: localized and locally advanced disease." Expert Rev Anticancer Ther **6**(4): 595-603.
- Sruogis, A., F. Jankevicius, et al. (2005). "[Prostatic biopsy technique. Historical review]." Medicina (Kaunas) **41**(11): 957-67.
- Stanford, J. L., K. G. Wicklund, et al. (1999). "Vasectomy and risk of prostate cancer." Cancer Epidemiol Biomarkers Prev **8**(10): 881-6.
- Stenman, U. H., J. Leinonen, et al. (1991). "A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer." Cancer Res **51**(1): 222-6.
- Styles, R. A. and S. E. Seltzer (1985). "Re: CT staging of prostate cancer." Radiology **157**(3): 838.
- Swanson, G. P., R. E. Cupps, et al. (1994). "Definitive therapy for prostate carcinoma: Mayo Clinic results at 15 years after treatment." Br J Radiol **67**(801): 877-89.

- Swindle, P., J. A. Eastham, et al. (2005). "Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens." J Urol **174**(3): 903-7.
- Thompson, I. M. (2001). "Latent carcinoma of the prostate." Eur Urol **39 Suppl 4**: 41-2.
- Torri, V. and I. Floriani (2005). "Cyproterone acetate in the therapy of prostate carcinoma." Arch Ital Urol Androl **77**(3): 157-63.
- Tunn, U. W., N. Bruchofsky, et al. (2000). "[Intermittent androgen deprivation]." Urologe A **39**(1): 9-13.
- Tuerk, I., I. S. Deger, et al. (2001). "[Laparoscopic radical prostatectomy. Experiences with 145 interventions]." Urologe A **40**(3): 199-206.
- van den Ouden, D. and F. H. Schroder (2000). "Management of locally advanced prostate cancer. 1. Staging, natural history, and results of radical surgery." World J Urol **18**(3): 194-203.
- van der Kwast, T. H. and M. J. Roobol (2006). "Can PSA density be used to detect prostate cancer?" Nat Clin Pract Urol **3**(3): 130-1.
- Van Poppel, H., H. Goethuys, et al. (2001). "[The role of radical prostatectomy in cT3 prostate carcinoma]." Schweiz Rundsch Med Prax **90**(38): 1623-31.
- Veliev, E. I., S. B. Petrov, et al. (2005). "[The role of a positive surgical margin after retropubic radical prostatectomy in prognosis of recurrent prostatic cancer]." Urologiia(5): 6-9.
- Vercelli, M., A. Quaglia, et al. (2000). "Prostate cancer incidence and mortality trends among elderly and adult Europeans." Crit Rev Oncol Hematol **35**(2): 133-44.
- Waehre, H., E. H. Wanderaas, et al. (1992). "Prediction of pelvic lymph node metastases by a prostate-specific antigen and prostatic acid phosphatase in clinical T3/T4M0 prostatic cancer." Eur Urol **22**(1): 33-8.
- Walsh, P. C. (1988). "Nerve sparing radical prostatectomy for early stage prostate cancer." Semin Oncol **15**(4): 351-8.
- Wammack, R., B. Djavan, et al. (2001). "Morbidity of transrectal ultrasound-guided prostate needle biopsy in patients receiving immunosuppression." Urology **58**(6): 1004-7.
- Watanabe, H. (2001). "Mass screening program for prostatic cancer in Japan." Int J Clin Oncol **6**(2): 66-73.
- Waterbor, J. W. and A. J. Bueschen (1995). "Prostate cancer screening (United States)." Cancer Causes Control **6**(3): 267-74.

- Wawroschek, F., H. Vogt, et al. (2001). "Radioisotope guided pelvic lymph node dissection for prostate cancer." J Urol **166**(5): 1715-9.
- Whitmore, W. F., Jr. (1990). "Natural history of low-stage prostatic cancer and the impact of early detection." Urol Clin North Am **17**(4): 689-97.
- Wiegel, T. and W. Hinkelbein (2002). "Radiotherapy after radical prostatectomy in patients with prostate-specific antigen elevation." Front Radiat Ther Oncol **36**: 35-42.
- Wiegel, T., R. Schmidt, et al. (1992). "Advantage of three-dimensional treatment planning for localized radiotherapy of early stage prostatic cancer." Strahlenther Onkol **168**(12): 692-7.
- Wilt, T. J. and M. K. Brawer (1997). "The Prostate Cancer Intervention Versus Observation Trial (PIVOT)." Oncology (Williston Park) **11**(8): 1133-9; discussion 1139-40, 1143.
- Wittekind, C. and G. Wagner, Eds. (2002). TNM-Klassifikation maligner Tumoren. Berlin, Heidelberg, Springer-Verlag.
- Yorozu, A., K. Toya, et al. (2006). "[Brachytherapy for prostate cancer.]." Gan To Kagaku Ryoho **33**(4): 424-7.
- Zerbib, M. (2005). "[GnRH analogs and prostate cancer treatment]." Ann Urol (Paris) **39 Suppl 3**: S66-72.
- Zincke, H., W. Lau, et al. (2001). "Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer." J Urol **166**(6): 2208-15.